Kodiak Sciences Inc (KOD) Stock Analysis

Q: What is the KOD stock price target?

Take-profit $54.52 (+50.9% upside). Prior stop was $33.60.

Q: Is KOD overvalued or undervalued?

Kodiak Sciences Inc trades at a P/E of N/A (forward -11.0). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about KOD?

11 analysts cover KOD with a consensus score of 4.0/5. Average price target: $63.

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 5 hr ago (May 20, 2026, 12:06 PM ET)

Healthcare · Biotechnology

$36.13+50.9% A.UpsideScore 4.8/10#106 of 157 Biotechnology

QualityF-score4 / 9FCF yield-2.42%

Stop $33.60Target $54.52(analyst − 13%)A.R:R 3.4:1

Analyst target$62.67+73.4%6 analysts

$54.52our TP

$36.13price

$62.67mean

$80

Sell if holding. Engine safety override at $36.13: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.8/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 84d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Recent Developments — Kodiak Sciences Inc

Latest news

This Pitney Bowes Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday — benzinga May 11, 2026 neutral
Chardan Capital Upgrades Kodiak Sciences to Buy, Raises Price Target to $61 — benzinga May 11, 2026 positive
Kodiak Sciences Q1 EPS $(0.94) Misses $(0.92) Estimate — benzinga May 7, 2026 negative
Kodiak Sciences' KSI-101 MESI Data From Tertiary Care Uveitis Practice Consistent With Phase 1b APEX Study Results — benzinga May 1, 2026 positive
Russell 2000 Rips To Record High — Here Are The Top Small Cap Gainers — benzinga Apr 17, 2026 positive

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (2.2 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-11.0

Mkt Cap$2.2B

EV/EBITDA-9.3

Profit Mgn0.0%

ROE-208.8%

Rev Growth—

Beta2.32

DividendNone

Rating analysts11

Quality Signals

Piotroski F4/9

Options Flow

P/C0.29bullish

IV90%elevated

Max Pain$24-33.6% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality2.215%0.33

Growth5.015%0.75

Momentum2.710%0.27

Sentiment7.610%0.76

Insider Activity3.910%0.39

Peer Rank2.510%0.25

Technical Setup6.35%0.32

Risk Profile3.05%0.15

Catalyst4.85%0.24

Overall (Σ contributions)4.81

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roa

0.0

Gross Margin

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Moat

4.0

Piotroski F

4.4

Current Ratio

9.5

Cash-burning (FCF negative)No competitive moatQuality concerns

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

0.0

Value Rank

5.0

Growth Rank

5.0

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd

0.0

Volume

0.0

Obv

1.0

Ma Position

4.0

Rsi

8.4

Uptrend pullback (RSI 31) - buy opportunityVolume distribution (falling OBV)Above 200-day MA

GatesMomentum 2.7<4.5A.R:R 3.4 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 84d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive

RSI

31 · Neutral

↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $32.93Resistance $47.00

Price Targets

$34

$55

A.Upside+50.9%

A.R:R3.4:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (2.2 < 4.0)

! Momentum score 2.7/10 — below 4.5 minimum

Earnings

3/4 beats

Next Earnings2026-08-12 (84d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is KOD stock a buy right now?

Sell if holding. Engine safety override at $36.13: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $33.60. Score 4.8/10, moderate confidence.

What is the KOD stock price target?

Take-profit target: $54.52 (+50.9% upside). Prior stop was $33.60. Stop-loss: $33.60.

What are the risks of investing in KOD?

Quality below floor (2.2 < 4.0).

Is KOD overvalued or undervalued?

Kodiak Sciences Inc trades at a P/E of N/A (forward -11.0). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about KOD?

11 analysts cover KOD with a consensus score of 4.0/5. Average price target: $63.

What does Kodiak Sciences Inc do?Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and...

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.